Wegovy (Semaglutide) Insurance Denial Appeal Guide

Why Wegovy Gets Denied

The most common denial reasons for Wegovy:

1. Not medically necessary — insurer doesn't consider obesity a disease
2. Cosmetic/lifestyle exclusion — plan excludes weight loss drugs
3. Step therapy required — must try cheaper alternatives first
4. Formulary exclusion — not on the plan's drug list
5. Quantity limits — insurer limits the dosage or duration

Medical Necessity Arguments

Wegovy is FDA-approved for chronic weight management in adults with:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)

Key Clinical Evidence

• STEP 1 Trial: 14.9% mean body weight reduction over 68 weeks
• STEP 3 Trial: 16% weight loss with intensive behavioral therapy
• STEP 4 Trial: Continued treatment prevented weight regain
• Cardiovascular benefit: SELECT trial showed 20% reduction in MACE events

Obesity as a Disease

• AMA recognized obesity as a disease in 2013
• WHO classifies obesity as a chronic disease (ICD-10 code E66)
• Over 200 comorbidities linked to obesity

Appeal Strategy

1. Get a letter of medical necessity from your prescribing physician documenting your BMI, comorbidities, and failed prior interventions
2. Document failed alternatives — list diet, exercise, and any other weight management attempts
3. Cite the SELECT trial — cardiovascular benefit makes this a medical intervention, not cosmetic
4. Reference state mandates — some states require coverage for FDA-approved obesity treatments
5. Request formulary exception — if excluded from formulary, apply for a coverage exception

Cost Without Insurance

Wegovy's retail price is approximately $1,350/month without insurance, making the appeal worth pursuing.